<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00823602</url>
  </required_header>
  <id_info>
    <org_study_id>1387YAZDRCCI</org_study_id>
    <nct_id>NCT00823602</nct_id>
  </id_info>
  <brief_title>Agonist Gonadotropin-Releasing Hormone (GnRH) Versus Antagonist GnRH</brief_title>
  <official_title>Comparison Between GnRH Agonist Long Protocol And GnRH Antagonist Protocol In Outcome Of The First Cycle ART</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yazd Research &amp; Clinical Center for Infertility</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yazd Research &amp; Clinical Center for Infertility</source>
  <brief_summary>
    <textblock>
      Literature suggests that GnRH antagonists are comparatively more often used in cycles which
      have an unfavorable prior prognosis, and this protocol is an ideal one for poor responder
      patients. Up to now, however not enough prospectives have been published to prove any
      beneficial effect of antagonists on the first cycle assisted reproductive technique.

      This prospective study will do to evaluate the efficacy of gonadotropin releasing hormone
      antagonist in comparison with the standard long protocol in the first cycle of ART.

      The investigators will randomize 160 patients undergoing ART for the first time . Group 1
      (n=80) was stimulate with a standard long protocol and group 2 (n=80) stimulated with GnRH
      antagonist and then result of ART compare in two group .
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2008</start_date>
  <completion_date type="Anticipated">January 2009</completion_date>
  <primary_completion_date type="Actual">October 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>pregnancy rate</measure>
    <time_frame>2weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>ovarian stimulation</measure>
    <time_frame>10days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">2</enrollment>
  <condition>Infertility</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GnRH antagonist &quot;ganirelix&quot; 0.25 mg fromm 6th ovarian stimulation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>GnRH agonist, suprefact, stimulation with a standard long protocol</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ganirelix</intervention_name>
    <description>These patients started ovarian stimulation with 150 - 225 IU Gonal F on the second day of menstrual cycle with an S.C. injection once a day. Initiation of 0.25 mg Ganirelix took place on the 6th of the stimulation (fixed protocol) when HMG (Menogon, ferring, pharmacenticals , Germany ).</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>suprefact</intervention_name>
    <description>GnRH agonist, standard protocol</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  first cycle of ART

          -  age &lt; 35 years

          -  basal FSH &lt; 10 IU/L

        Exclusion Criteria:

          -  previous IVF or ICSI, hyperprolactinemia, hyperthyroidism, hypothyroidism, uterine
             abnormality, severe endometriosis

          -  only one ovary
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>razieh firouzabadi, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Yazd Research &amp; Clinical Center for Infertility</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>razieh firouzabadi, MD</last_name>
    <phone>8247085</phone>
    <phone_ext>+98351</phone_ext>
    <email>dr_firouzabadi@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>shahnaz Ahmadi, MD</last_name>
    <phone>9173717981</phone>
    <phone_ext>+98</phone_ext>
    <email>AHMADISHAHNAZ2005@yahoo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Yazd Research and Clinical Center For Infertility</name>
      <address>
        <city>Yazd</city>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>razieh firouzabadi, MD</last_name>
      <phone>8247085</phone>
      <phone_ext>+98351</phone_ext>
      <email>dr_firouzabadi@yahoo.com</email>
    </contact>
    <contact_backup>
      <last_name>shahnaz Ahmadi, MD</last_name>
      <phone>9173717981</phone>
      <phone_ext>+98</phone_ext>
      <email>AHMADISHAHNAZ2005@yahoo.com</email>
    </contact_backup>
    <investigator>
      <last_name>shahnaz ahmadi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <verification_date>January 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 13, 2009</study_first_submitted>
  <study_first_submitted_qc>January 14, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 15, 2009</study_first_posted>
  <last_update_submitted>January 14, 2009</last_update_submitted>
  <last_update_submitted_qc>January 14, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 15, 2009</last_update_posted>
  <responsible_party>
    <name_title>Razieh Dehghani Firouzabadi</name_title>
    <organization>Yazd Research &amp; Clinical Center for Infertility</organization>
  </responsible_party>
  <keyword>GnRH antagonist</keyword>
  <keyword>GnRH agonist</keyword>
  <keyword>pregnancy rate</keyword>
  <keyword>Ovarian stimulation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Deslorelin</mesh_term>
    <mesh_term>Triptorelin Pamoate</mesh_term>
    <mesh_term>Buserelin</mesh_term>
    <mesh_term>Ganirelix</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

